References
- ParidaensADMinassianDCMccartneyACHungerfordJLPrognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 casesBr J Ophthalmol19947842522598199108
- KikuchiIKaseSIshijimaKIshidaSLong-term follow-up of conjunctival melanoma treated with topical interferon alpha-2b eye drops as adjunctive therapy following surgical resectionGraefes Arch Clin Exp Ophthalmol2017255112271227628752368
- HeindlLMHofmann-RummeltCAdlerWPrognostic significance of tumor-associated lymphangiogenesis in malignant melanomas of the conjunctivaOphthalmology2011118122351236021835473
- GoelHLMercurioAMVEGF targets the tumour cellNat Rev Cancer2013131287188224263190
- RefaianNSchlerethSLKochKRComparing the hem- and lymphangiogenic profile of conjunctival and uveal melanoma cell linesInvest Ophthalmol Vis Sci20155695691569726313304
- ShieldsJAShieldsCLDe PotterPSurgical management of circumscribed conjunctival melanomasOphthalmic Plast Reconstr Surg19981432082159612814
- XuQZhaoGQZhaoJExpression and significance of factors related to angiogenesis in choroidal melanomaInt J Ophthalmol201141495422553608
- KaseSOsakiMHonjoSExpression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomasVirchows Arch2003442212913512596063
- KinoshitaSKaseSAndoRExpression of vascular endothelial growth factor in human ocular adnexal lymphomaInvest Ophthalmol Vis Sci20145563461346724825110
- SimonettiOLucariniGRubiniCMicrovessel density and VEGF, HIF-1α expression in primary oral melanoma: correlation with prognosisOral Dis201319662062723279259
- SalvenPHeikkiläPJoensuuHEnhanced expression of vascular endothelial growth factor in metastatic melanomaBr J Cancer19977679309349328154
- UgurelSRapplGTilgenWReinholdUIncreased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survivalJ Clin Oncol200119257758311208853
- AsciertoPALeonardiEOttaianoANapolitanoMScalaSCastelloGPrognostic value of serum VEGF in melanoma patients: a pilot studyAnticancer Res20042464255425815736481
- WanXZhuYZhangLHouWGefitinib inhibits malignant melanoma cells through the VEGF/AKT signaling pathwayMol Med Rep20181757351735529568946
- MojaLLucenteforteEKwagKHSystemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationCochrane Database Syst Rev20149CD011230
- AbouammohMSharmaSRanibizumab versus bevacizumab for the treatment of neovascular age-related macular degenerationCurr Opin Ophthalmol201122315215821483262
- KochKRRefaianNHosDAutocrine impact of VEGF-A on uveal melanoma cellsInvest Ophthalmol Vis Sci20145542697270424677103
- LiJCuiYWangQThe proliferation of malignant melanoma cells could be inhibited by ranibizumab via antagonizing VEGF through VEGFR1Mol Vis20142064966024868139
- CorriePGMarshallANathanPDAVAST-M InvestigatorsAdjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trialAnn Oncol20182981843185230010756
- CorriePGMarshallADunnJAAdjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 studyLancet Oncol201415662063024745696
- el FilaliMLyLVLuytenGPBevacizumab and intraocular tumors: an intriguing paradoxMol Vis2012182454246723077404
- el FilaliMMissottenGSMaatWRegulation of VEGF-A in uveal melanomaInvest Ophthalmol Vis Sci20105152329233720042655